Bluejay Diagnostics, Inc.

BJDX

US0956333019

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-06-14 EDT			5-day change	1st Jan Change
0.51 ^USD	+11.62%		+17.78%	-58.20%

05-31	Bluejay Diagnostics, Inc. announced a financing transaction	CI
05-15	Bluejay Diagnostics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Bluejay Diagnostics, Inc. announced that it has received $1.59084 million in funding

August 27, 2023

On August 28, 2023, Bluejay Diagnostics, Inc. closed the transaction.

Latest news about Bluejay Diagnostics, Inc.

Bluejay Diagnostics, Inc. announced a financing transaction	05-30	CI
Bluejay Diagnostics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-15	CI
Bluejay Diagnostics, Inc. Appoints Neil Dey as Principal Financial and Accounting Officer	04-02	CI
Bluejay Diagnostics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-28	CI
Top Premarket Decliners	12-28	MT
Top Midday Decliners	12-27	MT
Bluejay Diagnostics, Inc. Announces Initiation of Multicenter Clinical Study Evaluating Symphony IL-6 in Sepsis Patients	12-27	CI
Bluejay Diagnostics Starts Clinical Study of Symphony IL-6 Test in Sepsis Patients; Shares Fall	12-27	MT
Bluejay Diagnostics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
Bluejay Diagnostics, Inc. Announces CFO Changes	23-10-02	CI
Bluejay Diagnostics, Inc. announced that it has received $1.59084 million in funding	23-08-27	CI
Sector Update: Health Care Stocks Climbing Late Afternoon	23-08-25	MT
Sector Update: Health Care Stocks Higher in Afternoon Trading	23-08-25	MT
Bluejay Diagnostics to Raise $1.6 Million in Registered Direct Offering	23-08-25	MT
Bluejay Diagnostics, Inc. announced that it expects to receive $1.59084 million in funding	23-08-23	CI
Bluejay Diagnostics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
North American Morning Briefing : Stocks Seen -2-	23-08-04	DJ
Dawson James Downgrades Bluejay Diagnostics to Neutral From Buy	23-08-03	MT
Bluejay Diagnostics Files $25 Million Mixed Shelf	23-06-06	MT
Bluejay Diagnostics, Inc. Updates Symphony IL-6 Regulatory Strategy	23-05-19	CI
Bluejay Diagnostics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-10	CI
Sector Update: Health Care Stocks Lifted with Broader Markets	23-03-21	MT
Top Midday Decliners	23-03-21	MT
Sector Update: Health Care Stocks Still Struggling for Firm Direction Tuesday Afternoon	23-03-21	MT
Top Premarket Decliners	23-03-21	MT

Chart Bluejay Diagnostics, Inc.

Duration

Period

More charts

Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a rapid, near-patient testing system for triage and monitoring of disease progression. Its product candidate, an IL-6 Test for sepsis triage, is designed to provide results in approximately 20 minutes from sample-to-result to help medical professionals make earlier and better triage/treatment decisions. The Symphony platform is a combination of its intellectual property (IP) and exclusively licensed and patented IP that consists of a mobile device and single-use test cartridges. The Symphony platform and its initial biomarker test, Symphony IL-6 test, is suited to address a subset of the global in vitro diagnostics devices market, including sepsis, cardio-metabolic diseases, cancer and other diseases that require rapid tests. Symphony targets critical care markets where physicians must quickly determine patient acuity to identify optimal treatment regimens.

Sector

Biotechnology & Medical Research

Calendar

2024-11-06 - Q3 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
BLUEJAY DIAGNOSTICS, INC.	-58.20%	1.48M
EXACT SCIENCES CORPORATION	-43.39%	7.73B
GUARDANT HEALTH, INC.	+11.68%	3.7B
IOVANCE BIOTHERAPEUTICS, INC.	+0.37%	2.28B
BGI GENOMICS CO., LTD.	-21.21%	1.99B
VERACYTE, INC.	-23.77%	1.6B
CAREDX, INC	+18.25%	739M
SEEGENE, INC.	-10.04%	687M
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-36.12%	461M
CURIOX BIOSYSTEMS CO., LTD	-4.47%	279M

Bio Diagnostics & Testing